FindTrial
Sign In

Nivolumab/Ipilimumab

BIOLOGICAL4 trials

Sponsors

AIO-Studien-gGmbH, University of Texas Southwestern Medical Center, University Hospital Heidelberg

Conditions

Advanced CancerCancer of Unknown Primary SiteCarcinoma, Renal CellClear-cell Metastatic Renal Cell CarcinomaKidney CancerKidney Cancer MetastaticKidney Cancer, Stage IVMetastatic Cancer

Phase 2

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
CompletedNCT02917772
AIO-Studien-gGmbHCarcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma
Start: 2016-10-31End: 2022-10-31Updated: 2022-10-06
SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients
CompletedNCT03065179
University of Texas Southwestern Medical CenterKidney Cancer, Kidney Cancer Metastatic, Kidney Cancer, Stage IV
Start: 2017-03-01End: 2020-11-17Updated: 2021-03-30
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma
NCT03219775
AIO-Studien-gGmbHAdvanced Cancer, Metastatic Cancer, Transitional Cell Carcinoma
Start: 2017-07-06End: 2023-02-18Updated: 2021-11-03
Nivolumab/Ipilimumab in Second Line CUP-syndrome
NCT04131621
University Hospital HeidelbergCancer of Unknown Primary Site
Start: 2019-12-12End: 2022-12-31Target: 194Updated: 2020-04-15

Related Papers

Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients-exploratory results from TITAN-RCC.
2025-08-28
Serum and tumor immune cell distribution as predictor of response to immune checkpoint blockade in solid tumors.
Journal of Clinical Oncology2025-05-28
Reasonability of Frequent Laboratory Analyses during Therapy with Nivolumab and Nivolumab+Ipilimumab in Patients with Advanced or Metastatic Renal Cell Carcinoma during the Phase 2 Clinical Trial TITAN-RCC
Cancers2024-06-20
Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma
JAMA Oncology2024-05-095 citations
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial.
2023-10-2421 citations
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.
2023-10-1323 citations
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
2023-02-289 citations
Novel predictive biomarkers of response to immune checkpoint blockade with nivolumab ± ipilimumab in the TITAN-RCC phase 2 trial.
Journal of Clinical Oncology2022-02-16
Efficacy of nivolumab/ipilimumab in patients with initial or late progression with nivolumab: Updated analysis of a tailored approach in advanced renal cell carcinoma (TITAN-RCC).
Journal of Clinical Oncology2021-05-2034 citations
Tailored immunotherapy approach with nivolumab in advanced transitional cell carcinoma (TITAN-TCC).
Journal of Clinical Oncology2021-02-202 citations
Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC).
Journal of Clinical Oncology2020-02-1984 citations